During a live event, Carol Ann Huff, MD, and participants discussed real-world evidence and personal experiences with talquetamab in relapsed/refractory multiple myeloma.

InoPd with inobrodib 20 mg previously demonstrated response rates at least 2x greater than alternatives for heavily pretreated pomalidomide-refractory patients following bispecific T cell engager or ...

European regulators recommended a subcutaneous formulation for a key anti-CD38 therapy, offering clinicians and patients more flexible administration options for multiple myeloma.

C4 Therapeutics has begun dosing in a Phase Ib study assessing cemsidomide and elranatamab (Elrexfio) in patients with ...

Dr. Nooka presents a case-based approach to treatment selection using a 50-year-old woman with relapsed/refractory multiple myeloma who progressed after 15 months on lenalidomide maintenance following ...

Bristol Myers Squibb BMY has delivered a strong performance year to date with its shares gaining 10.2% compared with the ...

Findings from Spherix Global Insights’ research reveal nearly three-quarters anticipate frontline use, with significant ...

There are now two very powerful but very different approaches that can be considered as early as first relapse for patients ...

Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) - ...

RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR ...